Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Published byریحانه احمدی Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2. Response to repeat dosing of chimpanzees with ARC-520."— Presentation transcript:

1 Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Response to repeat dosing of chimpanzees with ARC-520. (A) After a prestudy evaluation, nine chimpanzees began daily oral NUC dosing. After a variable NUC lead-in period to reduce viremia, NUC treatment continued concomitant with Q4W dosing of ARC-520 that began on day 1. Dosing days are indicated by vertical dashed lines. Blood samples were collected periodically throughout the study, and serum HBV DNA (B), HBeAg (C), and HBsAg (D and E) were measured and are shown for individual animals. (F) Mean log10 change in HBsAg for the 8 weeks preceding the first dose of ARC-520 and during ARC-520 treatment of four HBeAg-positive (●) and four HBeAg-negative (□) and in the HBeAg transitional chimpanzee (▲). BLD, below the limit of detection. *, chimpanzee 89A008 transitioned from HBeAg-positive to HBeAg-negative during the NUC lead-in period. Boxes in (B) and (C) indicate the first day of daily ETV dosing. Christine I. Wooddell et al., Sci Transl Med 2017;9:eaan0241 Published by AAAS

Download ppt "Fig. 2. Response to repeat dosing of chimpanzees with ARC-520."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
LTB4 production is elevated in preclinical and clinical lymphedema

LTB4 production is elevated in preclinical and clinical lymphedema
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.

Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.
Effects of highly concentrated SFN provided as BSE in T2D patients

Effects of highly concentrated SFN provided as BSE in T2D patients
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Specific antibiotics reduce fecal biomass in mice and humans.

Fig. 4. Specific antibiotics reduce fecal biomass in mice and humans.
Fig. 4. Hydrogel particle size and gelation mechanism.

Fig. 4. Hydrogel particle size and gelation mechanism.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Similar presentations

Ads by Google